ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus

Kidney International

Volumn 67, Issue 3, 2005, Pages 1033-1037

  Lansang, M Cecilia ^a   Stevanovic, Radomir ^b   Price, Deborah A ^b   Laffel, Lori M B ^b   Hollenberg, Norman K ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE

Author keywords

Chymase; Diabetes mellitus; Renal hemodynamics; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; BENZIMIDAZOLE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD VESSEL; KIDNEY PLASMA FLOW; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; DRUG EFFECT; KIDNEY CIRCULATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; BENZIMIDAZOLES; CAPTOPRIL; DIABETES MELLITUS, TYPE 1; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; PEPTIDYL-DIPEPTIDASE A; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 20844457947     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00167.x     Document Type: Article

References (26)

1. HOLLENBERG NK, OSEI SY, LANSANG MC, et al: Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. J Renin Angiotensin Aldosterone Syst 2:14-18, 2001
2. HUANG XR, CHEN WY, TRUONG LD, LAN HY: Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14:1738-1747, 2003
3. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197, 1997
4. LANSANG MC, OSEI SY, PRICE DA, et al: Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension 36:834-838, 2000
5. LANSANG MC, PRICE DA, LAFFEL LM, et al: Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 59:1432-1438, 2001
6. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
7. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
8. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
9. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
10. FUKAMI H, OKUNISHI H, MIYAZAKI M: Chymase: Its pathophysiological roles and inhibitors. Curr Pharm Des 4:439-453, 1998
11. WOLNY A, CLOZEL JP, REIN J, et al: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 80:219-227, 1997
12. OSEI SY, PRICE DA, LAFFEL LM, et al: Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 36:122-126, 2000
13. OSEI SY, PRICE DA, FISHER ND, et al: Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. Hypertension 33:559-564, 1999
14. MILLER JA: Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10:1778-1785, 1999
15. LANSANG MC, OSEI SY, COLETTI C, et al: Hyperglycaemia-induced intrarenal RAS activation: The contribution of metabolic pathways. J Renin Angiotensin Aldosterone Syst 3:19-23, 2002
16. MARRE M, BERNADET P, GALLOIS Y, et al: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
17. MARRE M, JEUNEMAITRE X, GALLOIS Y, et al: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 99:1585-1595, 1997
18. BARNAS U, SCHMIDT A, ILLIEVICH A, et al: Evaluation of risk factors for the development of nephropathy in patients with IDDM: Insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control. Diabetologia 40:327-331, 1997
19. RINGEL J, BEIGE J, KUNZ R, et al: Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension. Diabetologia 40:193-199, 1997
20. KUNZ R, BORK JP, FRITSCHE L, et al: Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: A methodologic appraisal and systematic review. J Am Soc Nephrol 9:1653-1663, 1998
21. PARVING HH, TARNOW L, ROSSING P: Genetics of diabetic nephropathy. J Am Soc Nephrol 7:2509-2517, 1996
22. DUDLEY CR, KEAVNEY B, STRATTON IM, et al: U.K. Prospective Diabetes Study: XV. Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Kidney Int 48:1907-1911, 1995
23. SCHMIDT S, SCHONE N, RITZ E: Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. Kidney Int 47:1176-1181, 1995
24. FISHER NDL, ALLAN D, KIFOR I, et al: Responses to converting enzyme and renin inhibition: Role of angiotensin II in humans. Hypertension 23:44-51, 1999
25. HOLLENBERG NK, FISHER ND, PRICE DA: Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 32:387-392, 1998
26. GAINER JV, MORROW JD, LOVELAND A, et al: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285-1292, 1998